Cahill Represents Financing Sources in Merger Financing for Envision Healthcare
Date: 12/01/16
Cahill represented the administrative agents, collateral agents, and lead arrangers in connection with establishing a new $850,000,000 asset-based revolving credit facility and $3,495,000,000 Term B loan. The transactions were completed in connection with Envision Healthcare’s merger with AmSurg Corp.
Also in connection with the merger, Cahill represented (i) the initial purchasers in connection with the Rule 144A offering of $550,000,000 aggregate principal amount of 6.25% Senior Notes due 2024 by New Amethyst Corp., to be renamed Envision Healthcare Corporation, (ii) the solicitation agents in connection with the solicitation of consents with respect to Amsurg Corp’s 5.625% Senior Notes due 2022 and (iii) the dealer managers in connection with the offer to purchase and solicitation of consents with respect to Amsurg Corp’s 5.625% Senior Notes due 2020.